Is Shopify Stock Still a Buy in 2025 or Has Growth Peaked?
The big picture trends in e‑commerce sales are clearly in…
Buy
73
TMDX Quote, Financials, Valuation and Earnings
Last price:
$92.25
Seasonality move
:
30.23%
Day range:
$89.65 - $93.95
52-week range:
$55.00 - $177.37
Dividend yield:
0%
P/E ratio:
89.09x
P/S ratio:
7.18x
P/B ratio:
13.25x
Volume:
682.9K
Avg. volume:
1.1M
1-year change:
-27.69%
Market cap:
$3B
Revenue:
$441.5M
EPS (TTM):
$1.01
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TMDX
TransMedics Group
|
$123.4M | $0.24 | 27.41% | -31.06% | $105.29 |
|
AXGN
Axogen
|
$48.3M | $0.02 | 16.84% | -76% | $25.71 |
|
ELMD
Electromed
|
$15.8M | -- | 13.91% | -- | $37.00 |
|
IRIX
IRIDEX
|
$12.8M | -$0.12 | -2.72% | -18.18% | -- |
|
MYO
Myomo
|
$9.2M | -$0.08 | 145.61% | -24% | $9.25 |
|
STXS
Stereotaxis
|
$6.9M | -$0.07 | -0.07% | -20.83% | $4.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TMDX
TransMedics Group
|
$89.98 | $105.29 | $3B | 89.09x | $0.00 | 0% | 7.18x |
|
AXGN
Axogen
|
$16.75 | $25.71 | $742.8M | -- | $0.00 | 0% | 3.96x |
|
ELMD
Electromed
|
$22.64 | $37.00 | $193.7M | 30.19x | $0.00 | 0% | 3.40x |
|
IRIX
IRIDEX
|
$1.19 | -- | $20M | -- | $0.00 | 0% | 0.40x |
|
MYO
Myomo
|
$4.88 | $9.25 | $167.8M | -- | $0.00 | 0% | 5.66x |
|
STXS
Stereotaxis
|
$2.02 | $4.50 | $173.7M | -- | $0.00 | 0% | 6.39x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TMDX
TransMedics Group
|
69.02% | 3.653 | 24.3% | 7.25x |
|
AXGN
Axogen
|
31.37% | 1.036 | 6.53% | 1.88x |
|
ELMD
Electromed
|
-- | 2.545 | -- | 4.68x |
|
IRIX
IRIDEX
|
51.25% | 1.797 | 9.47% | 0.73x |
|
MYO
Myomo
|
-- | 2.360 | -- | 2.82x |
|
STXS
Stereotaxis
|
-- | 1.450 | -- | 0.74x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TMDX
TransMedics Group
|
$72M | $8.6M | 5.12% | 19.17% | 8.68% | $6.1M |
|
AXGN
Axogen
|
$37.6M | $2M | -6.89% | -10.21% | 4.56% | $7.9M |
|
ELMD
Electromed
|
$12.6M | $2.5M | 15.91% | 15.91% | 15.64% | $2.9M |
|
IRIX
IRIDEX
|
$4.3M | -$1.9M | -146.36% | -157.91% | -16.15% | -$3.1M |
|
MYO
Myomo
|
$8.6M | -$245.3K | -48.64% | -48.64% | -2.03% | $2.5M |
|
STXS
Stereotaxis
|
$3.2M | -$7.6M | -139.2% | -139.2% | -120.3% | $1.3M |
TransMedics Group vs. Competitors
-
Which has Higher Returns TMDX or AXGN?
Axogen has a net margin of 5.64% compared to TransMedics Group's net margin of 0.91%. TransMedics Group's return on equity of 19.17% beat Axogen's return on equity of -10.21%.
Company Gross Margin Earnings Per Share Invested Capital TMDXTransMedics Group59.21% $0.19 $737.9M AXGNAxogen76.06% $0.01 $151.4M -
What do Analysts Say About TMDX or AXGN?
TransMedics Group has a consensus price target of $105.29, signalling upside risk potential of 17.01%. On the other hand Axogen has an analysts' consensus of $25.71 which suggests that it could grow by 53.52%. Given that Axogen has higher upside potential than TransMedics Group, analysts believe Axogen is more attractive than TransMedics Group.
Company Buy Ratings Hold Ratings Sell Ratings TMDXTransMedics Group5 3 0 AXGNAxogen5 0 0 -
Is TMDX or AXGN More Risky?
TransMedics Group has a beta of 1.906, which suggesting that the stock is 90.573% more volatile than S&P 500. In comparison Axogen has a beta of 1.195, suggesting its more volatile than the S&P 500 by 19.457%.
-
Which is a Better Dividend Stock TMDX or AXGN?
TransMedics Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group pays -- of its earnings as a dividend. Axogen pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TMDX or AXGN?
TransMedics Group quarterly revenues are $121.6M, which are larger than Axogen quarterly revenues of $49.4M. TransMedics Group's net income of $6.9M is higher than Axogen's net income of $450K. Notably, TransMedics Group's price-to-earnings ratio is 89.09x while Axogen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group is 7.18x versus 3.96x for Axogen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMDXTransMedics Group7.18x 89.09x $121.6M $6.9M AXGNAxogen3.96x -- $49.4M $450K
-
Which has Higher Returns TMDX or ELMD?
Electromed has a net margin of 5.64% compared to TransMedics Group's net margin of 12.11%. TransMedics Group's return on equity of 19.17% beat Electromed's return on equity of 15.91%.
Company Gross Margin Earnings Per Share Invested Capital TMDXTransMedics Group59.21% $0.19 $737.9M ELMDElectromed77.68% $0.22 $43.6M -
What do Analysts Say About TMDX or ELMD?
TransMedics Group has a consensus price target of $105.29, signalling upside risk potential of 17.01%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 63.43%. Given that Electromed has higher upside potential than TransMedics Group, analysts believe Electromed is more attractive than TransMedics Group.
Company Buy Ratings Hold Ratings Sell Ratings TMDXTransMedics Group5 3 0 ELMDElectromed2 0 0 -
Is TMDX or ELMD More Risky?
TransMedics Group has a beta of 1.906, which suggesting that the stock is 90.573% more volatile than S&P 500. In comparison Electromed has a beta of 0.460, suggesting its less volatile than the S&P 500 by 53.993%.
-
Which is a Better Dividend Stock TMDX or ELMD?
TransMedics Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TMDX or ELMD?
TransMedics Group quarterly revenues are $121.6M, which are larger than Electromed quarterly revenues of $16.3M. TransMedics Group's net income of $6.9M is higher than Electromed's net income of $2M. Notably, TransMedics Group's price-to-earnings ratio is 89.09x while Electromed's PE ratio is 30.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group is 7.18x versus 3.40x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMDXTransMedics Group7.18x 89.09x $121.6M $6.9M ELMDElectromed3.40x 30.19x $16.3M $2M
-
Which has Higher Returns TMDX or IRIX?
IRIDEX has a net margin of 5.64% compared to TransMedics Group's net margin of -16.69%. TransMedics Group's return on equity of 19.17% beat IRIDEX's return on equity of -157.91%.
Company Gross Margin Earnings Per Share Invested Capital TMDXTransMedics Group59.21% $0.19 $737.9M IRIXIRIDEX37.33% -$0.12 $5.4M -
What do Analysts Say About TMDX or IRIX?
TransMedics Group has a consensus price target of $105.29, signalling upside risk potential of 17.01%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 68.07%. Given that IRIDEX has higher upside potential than TransMedics Group, analysts believe IRIDEX is more attractive than TransMedics Group.
Company Buy Ratings Hold Ratings Sell Ratings TMDXTransMedics Group5 3 0 IRIXIRIDEX0 0 0 -
Is TMDX or IRIX More Risky?
TransMedics Group has a beta of 1.906, which suggesting that the stock is 90.573% more volatile than S&P 500. In comparison IRIDEX has a beta of 0.692, suggesting its less volatile than the S&P 500 by 30.819%.
-
Which is a Better Dividend Stock TMDX or IRIX?
TransMedics Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TMDX or IRIX?
TransMedics Group quarterly revenues are $121.6M, which are larger than IRIDEX quarterly revenues of $11.6M. TransMedics Group's net income of $6.9M is higher than IRIDEX's net income of -$1.9M. Notably, TransMedics Group's price-to-earnings ratio is 89.09x while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group is 7.18x versus 0.40x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMDXTransMedics Group7.18x 89.09x $121.6M $6.9M IRIXIRIDEX0.40x -- $11.6M -$1.9M
-
Which has Higher Returns TMDX or MYO?
Myomo has a net margin of 5.64% compared to TransMedics Group's net margin of -2.16%. TransMedics Group's return on equity of 19.17% beat Myomo's return on equity of -48.64%.
Company Gross Margin Earnings Per Share Invested Capital TMDXTransMedics Group59.21% $0.19 $737.9M MYOMyomo71.39% -$0.01 $24.7M -
What do Analysts Say About TMDX or MYO?
TransMedics Group has a consensus price target of $105.29, signalling upside risk potential of 17.01%. On the other hand Myomo has an analysts' consensus of $9.25 which suggests that it could grow by 89.55%. Given that Myomo has higher upside potential than TransMedics Group, analysts believe Myomo is more attractive than TransMedics Group.
Company Buy Ratings Hold Ratings Sell Ratings TMDXTransMedics Group5 3 0 MYOMyomo3 0 0 -
Is TMDX or MYO More Risky?
TransMedics Group has a beta of 1.906, which suggesting that the stock is 90.573% more volatile than S&P 500. In comparison Myomo has a beta of 1.633, suggesting its more volatile than the S&P 500 by 63.336%.
-
Which is a Better Dividend Stock TMDX or MYO?
TransMedics Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TMDX or MYO?
TransMedics Group quarterly revenues are $121.6M, which are larger than Myomo quarterly revenues of $12.1M. TransMedics Group's net income of $6.9M is higher than Myomo's net income of -$260.1K. Notably, TransMedics Group's price-to-earnings ratio is 89.09x while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group is 7.18x versus 5.66x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMDXTransMedics Group7.18x 89.09x $121.6M $6.9M MYOMyomo5.66x -- $12.1M -$260.1K
-
Which has Higher Returns TMDX or STXS?
Stereotaxis has a net margin of 5.64% compared to TransMedics Group's net margin of -118.53%. TransMedics Group's return on equity of 19.17% beat Stereotaxis's return on equity of -139.2%.
Company Gross Margin Earnings Per Share Invested Capital TMDXTransMedics Group59.21% $0.19 $737.9M STXSStereotaxis50.73% -$0.09 $11.4M -
What do Analysts Say About TMDX or STXS?
TransMedics Group has a consensus price target of $105.29, signalling upside risk potential of 17.01%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 122.77%. Given that Stereotaxis has higher upside potential than TransMedics Group, analysts believe Stereotaxis is more attractive than TransMedics Group.
Company Buy Ratings Hold Ratings Sell Ratings TMDXTransMedics Group5 3 0 STXSStereotaxis2 0 0 -
Is TMDX or STXS More Risky?
TransMedics Group has a beta of 1.906, which suggesting that the stock is 90.573% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.461, suggesting its more volatile than the S&P 500 by 46.088%.
-
Which is a Better Dividend Stock TMDX or STXS?
TransMedics Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TransMedics Group pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TMDX or STXS?
TransMedics Group quarterly revenues are $121.6M, which are larger than Stereotaxis quarterly revenues of $6.3M. TransMedics Group's net income of $6.9M is higher than Stereotaxis's net income of -$7.5M. Notably, TransMedics Group's price-to-earnings ratio is 89.09x while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TransMedics Group is 7.18x versus 6.39x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TMDXTransMedics Group7.18x 89.09x $121.6M $6.9M STXSStereotaxis6.39x -- $6.3M -$7.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is RTX The Best Growth Stock?
Among the worldwide aerospace and defense markets, the US controls…
Is VFS Stock Cheap to Buy Now?
VinFast Auto (NASDAQ:VFS) is a leading EV manufacturer in Vietnam.…
Stock Ideas
Buy
71
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
63
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Buy
91
TRUP alert for May 5
Trupanion [TRUP] is down 0.38% over the past day.
Buy
60
RGC alert for May 6
Regencell Bioscience Holdings [RGC] is up 53.44% over the past day.
Sell
49
XYZ alert for May 5
Block [XYZ] is up 0.19% over the past day.
